Perseus PCI announces appointment of Buddy Long as President of Perseus PCI
Cayman Islands (PRWEB) April 05, 2013
Said Dr. Thomas Wagner, a founder and board member of Perseus PCI: “Buddy Long is a dedicated and entrepreneurial business leader. He is now determined to bring to patients the scientific breakthroughs my colleagues in the medical profession and I have had in our long fight to understand, treat and eliminate human cancers. I am delighted at the energy and speed with which he has found the funding, recruited our world-class licensed clinical staff, and established a patient-friendly venue in the Cayman Islands equipped and ready for us to begin operations immediately.”
Long is an English literature graduate of South Carolina’s Winthrop University, and has since served as a commissioned infantry officer in the U.S. Marine Corps. He also founded his own wholesale and retail insurance agency, which was sold in December 2002.
Said Long: “In his lifetime, Dr. Wagner has had the fortune and opportunity of being involved in the most important cancer research and clinical environments in history at a time when the scientific and medical professions were learning more about the human body than ever known before now. His understanding of the disease and his approach to defeating the disease is the product of this experience. This approach to immunotherapy – stimulating the existing immune system, which already eliminates cancer starts in all of us on a daily basis, not manipulating the immune system, simply makes sense. In a world that has lived with barbaric therapies for cancer since the earliest recorded diagnosis of the disease, Perseus PCI is introducing an effective alternative. Our treatment is an efficient killer of metastatic disease – but dignified and humane to the patient.”
About Perseus PCI
Perseus PCI is a cancer treatment center headquartered in the Cayman Islands. Perseus provides an effective treatment approach for solid-tumor cancers that produces little to no side effects and can be an alternative to chemotherapy and radiation. The therapy, which uses the natural immune system, is easily administered by injection under the skin surface once a month for four months. This technology’s safety and effectiveness has been proven in US FDA sanctioned trials. The US approval process is ongoing, but this treatment has been approved for manufacture and administration by the Health Practice Commission of the Cayman Islands.
The therapy offered by Perseus is a dendritic cell-based immunotherapy, which has already been shown to be effective against melanoma, renal cell carcinoma and neuroblastoma tumors. Dendritic cells can be stimulated to activate a cytotoxic (killer) response toward the particular tumor. The patient’s dendritic cells are loaded with all of the patient’s tumor cell components to make the vaccine. When the vaccine is administered to the patient, the dendritic cells, a type of antigen-presenting cell, present the tumor antigen to the effector lymphocytes (CD4+ T cells and CD8+ cells), which initiates a cytotoxic response against the tumor cells.